EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Extracorporeal Photopheresis in Heart Transplantation: From Salvage Therapy to Immunosuppression-Sparing Strategy

Allistair Nathan, Francisco Arabia, Jamal Mahar

Journal of Cardiac Failure · 2026

DOI: 10.1016/j.cardfail.2026.06.016 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cardiac Failure, 2026. Verfasst von Allistair Nathan und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Arizona College of Medicine-Phoenix, Phoenix, Arizona. Hauptthemen laut MEDLINE: Photopheresis, Heart Transplantation, Salvage Therapy, Graft Rejection. Die Arbeit nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart transplantation remains the definitive therapy for end-stage heart failure, yet graft survival continues to be limited by acute and chronic rejection and the cumulative toxicity of lifelong immunosuppression. Extracorporeal photopheresis (ECP), an immunomodulatory therapy with established efficacy in graft-versus-host disease and lung transplantation, has been investigated for more than 3 decades as an adjunctive therapy in heart transplantation. While prior reviews have summarized historical outcomes, the role of ECP in contemporary transplant practice remains incompletely defined. This state-of-the-art review examines the immunologic basis, clinical evidence, and evolving applications of ECP in heart transplant recipients, with particular focus on rejection prophylaxis, acute cellular rejection, recurrent rejection, and antibody-mediated processes. We contextualize existing evidence within modern immunosuppressive regimens and emerging noninvasive rejection surveillance tools, including donor-specific antibodies and molecular biomarkers. Beyond its role as salvage therapy, accumulating evidence suggests that ECP may function as an immunosuppression-sparing strategy, particularly in high-risk patients with recurrent rejection, infection vulnerability, or intolerance to intensified immunosuppression. We highlight unresolved knowledge gaps, propose patient selection frameworks, and identify future research directions necessary to define the role of ECP in modern heart transplantation. Overall, ECP appears to be a safe and underutilized adjunct with potential to reduce rejection burden while mitigating the long-term consequences of immunosuppression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhotopheresisHeart TransplantationSalvage TherapyGraft RejectionImmunosuppression TherapyHeart FailureHumansImmunosuppressive AgentsGraft Survival

Stichwörter der Autor:innen

ECPExtracorporeal photopheresisheart transplantrejection

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • University of Arizona College of Medicine-Phoenix, Phoenix, Arizona.
  • Banner University Medical Center-Phoenix, Phoenix, Arizona.
  • Banner University Medical Center-Phoenix, Phoenix, Arizona; Department of Cardiology, Section of Advanced Heart Failure, University of Arizona College of Medicine-Phoenix, Phoenix, Arizona. Electronic address: maharj@ar…

Zitieren

APA

Nathan, A., Arabia, F., & Mahar, J. (2026). Extracorporeal Photopheresis in Heart Transplantation: From Salvage Therapy to Immunosuppression-Sparing Strategy. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2026.06.016

Vancouver

Nathan A, Arabia F, Mahar J. Extracorporeal Photopheresis in Heart Transplantation: From Salvage Therapy to Immunosuppression-Sparing Strategy. Journal of Cardiac Failure. 2026. doi:10.1016/j.cardfail.2026.06.016

BibTeX
@article{Nathan2026,
  author = {Nathan, Allistair and Arabia, Francisco and Mahar, Jamal},
  title = {Extracorporeal Photopheresis in Heart Transplantation: From Salvage Therapy to Immunosuppression-Sparing Strategy},
  journal = {Journal of Cardiac Failure},
  year = {2026},
  doi = {10.1016/j.cardfail.2026.06.016}
}
Kostenlos starten →